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Inhibition of Amyloid Fiber Assembly
by Both BiP and Its Target Peptide
that a common folding intermediate underlies fibrillo-
genesis.
Of the proteins known to form amyloid deposits in
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humans, LC is unique in one respect: its sequence is*Department of Pathology and
highly polymorphic due to somatic hypermutation. OnCommittee on Immunology
average, each expressed human LC contains 10–12†Department of Molecular Genetics and Cell Biology
amino acid substitutions within the VL relative to itsThe University of Chicago
germline gene (Stevens et al., 1999). While essential forChicago, Illinois 60637
creating a large repertoire, one consequence of this‡Biosciences Division
sequence diversity is that many LC are associated withArgonne National Laboratory
protein deposition (Stevens and Argon, 1999a). AlthoughArgonne, Illinois 60439
there is no unique sequence identifying amyloidogenic
human VL, somatically mutated derivatives of a small
number of germline genes are overrepresented in LCSummary
deposits (Wilkins Stevens et al., 1995; Wetzel, 1997). A
prime example is the k4 gene: the germline sequenceImmunoglobulin light chain (LC) normally is a soluble,
encodes a soluble protein, but almost every other ex-secreted protein, but some LC assemble into ordered
pressed k4 sequence was found in AL patients (Denoroyfibrils whose deposition in tissues results in amy-
et al., 1994) or in patients with LC deposition disease,loidosis and organ failure. Here we reconstitute fibril
characterized by nonordered, amorphous LC depositsformation in vitro and show that preformed fibrils can
(Stevens et al., 1999). Thus, the k4 germline-encodednucleate polymerization of soluble LC. This prion-like
protein can be easily diverted by mutation into an aggre-behavior has important physiological implications,
gation pathway.since somatic mutations generate multiple related LC
Although k4 is a small, rarely used LC family, it illus-sequences. Furthermore, we demonstrate that fibril
trates one difficulty: since every aggregation-prone LCformation in vitro and aggregation of whole LC within
contains multiple somatic mutations, it is difficult to con-cells are inhibited by BiP and by a synthetic peptide
struct a simple relationship between somatic mutationthat is identical to a major LC binding site for BiP. We
and amyloidogenesis. Work with recombinant VL pro-propose that LC form fibrils via an interprotein loop
teins shows that the tendency of k4 sequences to formswap and that the underlying conformational change
fibrils is inversely correlated with their thermodynamicshould be amenable to drug therapy.
stability (Raffen et al., 1999). Moreover, while the muta-
tions found in expressed k4 sequences are both stabiliz-Introduction
ing and destabilizing, only destabilizing mutations pro-
mote fibril formation (Raffen et al., 1999). The ensembleLight chain amyloidosis (AL) is a fatal disease, character-
of k4 somatic mutants provides a unique experimentalized by deposition of protein fibrils that leads to failure
system, which we have utilized in an attempt to provideof the affected organ (Buxbaum et al., 1990). Although
a molecular explanation for fibril formation. Understand-AL most commonly accompanies multiple myeloma, pa-
ing how certain LC sequences become prone to fibriltients may present without any obvious malignancy. The
formation should enable the design of inhibitors of thisfibril deposits sometimes contain the complete immuno-
type of aggregation.
globulin LC but often consist of fragments encom-
In the normal folding environment, the endoplasmic
passing the LC variable domain (VL). In addition, purified reticulum (ER) of B lineage cells, molecular chaperones
VL is sufficient in vitro to polymerize into amyloid fibrils such as BiP prevent aggregation of LC (Stevens and
that exhibit the same characteristics as those derived Argon, 1999b). BiP binds to early folding intermediates
from patients (Raffen et al., 1999). Thus, the VL is thought of wild-type LC, and mutants that affect the folding of VLof as the aggregating domain of the light chain (LC). display increased association with BiP (Dul and Argon,
The pathology of AL is similar to other amyloidoses 1990; Ma et al., 1990; Hendershot et al., 1996; Davis et
and creates an interesting molecular puzzle. Fibrillogen- al., 1999). We and others have shown that BiP binds
esis requires the ability to polymerize in an ordered man- short peptides within LC and that the predominant bind-
ner, implying that the aggregating protein has folded to ing is to two peptides within the VL domain (Skowronek
a defined state. For example, the species of transthyretin et al., 1998; Davis et al., 1999). Building on this knowl-
that gives rise to fibrils is an advanced folding intermedi- edge, we asked if interaction with BiP is also relevant
ate of the monomer (Kelly et al., 1997). This is also the to the process of amyloid formation. We show here that
case with other amyloidogenic proteins (Booth et al., BiP does inhibit LC fibril formation in vitro as well as
1997). At least 18 proteins with diverse native folds are aggregation in the cell. We also show that predicted
known to form fibrils with reasonably similar ultrastruc- target peptides of BiP can be used as effective inhibitors
ture (Radford and Dobson, 1999). This supports the idea of fibril formation. These data support the hypothesis
that LC amyloid fibrils are assembled from a folding
intermediate in a domain-swapping interaction and pro-§ To whom correspondence should be addressed (e-mail: yargon@




Fibril Formation In Vitro
We used an agitation-based in vitro assay (Solomon et
al., 1998; Raffen et al., 1999) to assemble fibrils from
two k4 recombinant VL, LEN, and SMA. LEN was isolated
as a Bence Jones protein from a patient with no evidence
of amyloid deposits. It is a soluble, stable protein, dif-
fering from the germline k4 by only one somatic mutation
(Wilkins Stevens et al., 1995). SMA, although differing
from LEN by only eight amino acids, was isolated from
an AL patient (Wilkins Stevens et al., 1995) and has been
shown to be thermodynamically less stable than LEN
(Raffen et al., 1999). Upon incubation at 378C with shak-
ing, the amyloidogenic SMA spontaneously formed fi-
brils, as indicated by increased binding of thioflavin T
(Figure 1A) and binding of Congo red, resulting in green
birefrigence (Raffen et al., 1999), two properties typical
of amyloid fibrils. In contrast, the nonamyloidogenic pro-
tein LEN did not form fibrils under these conditions.
However, when treated with 1 M guanidine hydrochlo-
ride (GuHCl), LEN did form fibrils. As shown before (Raf-
fen et al., 1999), this treatment only mildly denatures
LEN, suggesting that a nonnative form of VL must be
achieved as a prerequisite for fibril formation.
Suspensions of dye binding aggregates of SMA were
also turbid (not shown) and in electron microscopy were
seen to form unbranched fibrils with an average diame-
ter of 8 nm (Figure 1B). These properties are comparable
Figure 1. Formation of LC Amyloid Fibrilsto those of fibrils identified from patients’ amyloid de-
(A) Time course of fibril formation by SMA and LEN. VL (160 mM)posits (Wetzel, 1997), in vitro–formed LEN fibrils (Raffen
were incubated with shaking at 378C; at the indicated times, 10 mMet al., 1999), and fibrils derived from other proteins
thioflavin T was added and the fluorescence measured. Results(Wood et al., 1996; Harper and Lansbury, 1997). Fibril
are presented as averages 6 standard deviation (SD) of several
formation in vitro was concentration dependent, and experiments with SMA (diamonds; n 5 3), LEN (open triangles; n 5
maximal polymerization occurred above 20 mM SMA 3), or LEN incubated in the presence of 1 M GuHCl (filled triangles;
(Figure 1C). Importantly, the minimal protein concentra- n 5 2). Data for LEN were normalized to the maximal fluorescence
level (19,000 6 3,200 relative fluorescence units) obtained with LENtion required in our assay for detectable fibril assembly
plus GuHCl; data for SMA were normalized to its maximal fluores-was 4 mM, which is approximately the concentration of
cence level (10,000 6 1,600 relative fluorescence units).LC in the ER of a plasma cell (Wiest et al., 1990). There-
(B) Electron micrograph of SMA fibrils negatively stained with uranyl
fore, the mechanism of fibril formation in our in vitro acetate. Bar, 50 nm.
assay may be relevant to amyloidosis in vivo. (C) Concentration dependence of SMA fibril formation. Amount of
fibrils formed after 92 hr at increasing concentrations of input SMA
is presented in arbitrary units of thioflavin T fluorescence 3 103.Seeding of Fibril Formation
(D) SMA fibril formation is a seeded reaction. Seeds were preparedThe ability of SMA to form fibrils is accelerated by seed-
by sonication of preformed SMA amyloid fibrils and added to the
ing, a feature characteristic of nucleated polymerization assay at the indicated percentage (w/w with soluble SMA). Thioflavin
reactions (Harper and Lansbury, 1997). Addition of 1%– T fluorescence was measured after 24 hr, a time point when sponta-
10% (w/w) sonicated, preformed SMA fibrils to a SMA neous fibril formation by SMA alone is marginal (A). Open diamonds,
amount of total fluorescence; open triangles, amount of fluores-solution enhanced polymerization in linear fashion (Fig-
cence contributed by the added fibrils; filled diamonds, net specificure 1D), as measured after only 24 hr of incubation, a
fluorescence after subtraction of background from total fluores-time when unseeded SMA did not form fibrils spontane-
cence; open circles, fluorescence in reactions seeded with heat-
ously (Figures 1A and 1E). Seeding also substantially induced (508C, 10 min), disordered SMA aggregates instead of pre-
increased the reproducibility of this polymerization. The formed fibrils. Data are presented in arbitrary units of thioflavin T
lowest concentration that reproducibly enhanced fibril- fluorescence 3 103 (n 5 3).
(E) Seeding accelerates the rate of fibril formation. Comparison oflogenesis, 5% seed, was chosen for further experi-
SMA fibril formation in an unseeded reaction and in a reactionments. In the absence of seed, the half-time for maximal
seeded with 5% (w/w) sonicated SMA fibrils. Note that the presenceSMA fibril assembly was .80 hr, while in the presence
of seed alters the kinetics of fibril assembly but does not affect total
of seed the half-time was reproducibly ,40 hr (Figure yield of fibrils. Data are presented in arbitrary units of thioflavin T
1E). The seeded reaction was largely independent of pH fluorescence 3 103 (n 5 3).
in the physiological range of 4 to 8, but exposure to
alkaline buffers significantly enhanced fibrillogenesis
(data not shown). Importantly, only sonicated or vigor- generated by heat denaturation, which are amorphous
and thioflavin T negative, did not seed fibril assemblyously vortexed (data not shown) SMA fibrils were capa-
ble of promoting VL polymerization; SMA aggregates (Figure 1D). Thus, the ability to nucleate is dependent
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on the type of seed and demonstrates high specificity
in the polymerization reaction. These data strongly indi-
cate a nucleation-mediated reaction where the forma-
tion of the nuclei is rate limiting, presumably due to
an unfavorable conformational change required in the
aggregating unit, which is likely to be a VL dimer (Raffen
et al., 1998).
A Single Somatic Mutation Is Sufficient to Convert
a Soluble LC to a Fibrillogenic LC
The readiness with which SMA adopts a fibrillogenic
conformation as compared to LEN must reside in the
minimal sequence differences between the two. We
therefore asked whether LEN could be induced to form
fibrils, in the absence of GuHCl, by seeding with pre-
formed SMA fibrils. LEN polymerized rapidly into fibrils
upon addition of SMA seed, while unseeded LEN re-
mained soluble (Figure 2A). Moreover, the total amount
of LEN fibrils was as great as that generated from SMA
(Figure 2B), and the properties of LEN fibrils were indis-
tinguishable from those of SMA fibrils. This indicates
that the native conformation of LEN is only quasi-stable
and can readily shift to become structurally complemen-
tary to the unstable conformation of SMA. Cross-seed-
ing of wild-type LC aggregation by a mutant is therefore
analogous to the induced conformational change ob-
served in prion-forming proteins (Kocisko et al., 1994).
Since only eight residues distinguish LEN and SMA,
each SMA mutation was substituted into LEN to identify
the residues that contribute most to the propensity to
form fibrils (Raffen et al., 1999). Each of the resultant
Figure 2. Sequence Dependence of Fibril Formationrecombinant proteins was tested with and without seed-
(A) Cross-seeding of LEN with SMA fibrils. Time course of LEN fibriling. As shown in Figure 2B, Q89H formed fibrils only
formation in the presence (closed triangles) and absence (open
when seeded with SMA. T94H and Y96Q did not form triangles) of 5% SMA fibril seed. In the absence of seed, LEN fails
fibrils spontaneously and did so only marginally even to form fibrils. When seeded with SMA, LEN efficiently polymerizes
when seeded. However, T94H fibril formation was en- into fibrils (in the absence of denaturants). Data are presented in
arbitrary units of thioflavin T fluorescence 3 103 (n 5 3).hanced by destabilization with GuHCl, consistent with
(B) Effects of individual somatic mutations on fibrillogenesis. SMA-the measured stabilizing effect of this mutation (Raffen
derived substitutions were introduced into LEN; each mutant nameet al., 1999). Although Y96Q was only minimally thioflavin
indicates the sequence position of the affected residue, with the
T positive, it formed aggregates to the same extent as LEN residue at this position before the number and the SMA residue
SMA, as measured by turbidity (data not shown). More- after the number. Fibril formation was assayed at 96 hr of incubation
over, Y96Q could not be seeded with aggregates of (n 5 3), in the presence (1) or absence (–) of SMA fibril seed. Thi-
oflavin T fluorescence was normalized to the maximal wild-type LENitself, consistent with this highly unstable mutant (Raffen
fluorescence (25,500 6 7,600 relative units). Open bars, seededet al., 1999) forming mostly nonfibrillar aggregates and
reactions; filled bars, unseeded reactions; gray bar, unseeded reac-only a small quantity of ordered fibrils. Of all the LEN
tion that included 1 M GuHCl.
mutants, only P40L spontaneously formed turbid, thi-
oflavin T–positive aggregates, though somewhat less
efficiently than SMA. P40L responded reproducibly to inhibited SMA fibril assembly (Figure 3A) and increased
seeding with SMA by polymerizing very efficiently (Fig- the fraction of VL that remained soluble (Figure 3B). BiP’s
ure 2B). Thus, the single P40L substitution appears to effect was specific, since proteins like lysozyme (Figure
be the primary contributing factor in the conversion of 3C), albumin, and ferritin (data not shown) did not signifi-
a soluble, wild-type LEN into a fibril former. cantly decrease fibril formation. Importantly, another ER
chaperone, GRP94, was far less efficient at inhibiting
fibril formation, whereas Hsp70, a BiP family member,The Chaperone BiP Inhibits Fibril Formation In Vitro
In the cellular environment, the ER chaperone BiP is was equally effective (Figure 3C). Addition of BiP or
Hsp70 to preformed fibrils did not reverse the aggrega-important for regulating LC folding. It interacts with early
folding intermediates of both wild-type and mutant LC, tion (data not shown). Remarkably, BiP prevented the
ordered aggregation at vastly substoichiometric ratios;primarily by binding to peptides in the VL domain (Mel-
nick et al., 1994; Skowronek et al., 1998; Davis et al., as little as 1 mol of BiP per 100 mol of SMA significantly
decreased the rate of fiber formation (Figure 3A). The1999), and persistent association with BiP delays LC
folding (Hendershot et al., 1996). Therefore, we exam- major effect of BiP was to increase the lag time, rather
than to reduce the final extent of aggregation (Figureined the interaction of BiP with SMA in vitro. Inclusion
of BiP in the seeded aggregation reaction dramatically 3A). In addition, the ability of SMA to assemble efficiently
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Figure 3. Inhibition of Fibrillogenesis by BiP
(A) BiP inhibits SMA fibril formation. Recom-
binant BiP was added to the fibril formation
assay at various molar ratios: 30 SMA:1 BiP
(diamonds), 100:1 (circles), and 300:1 (trian-
gles). Data from a representative experiment
(duplicate reactions) are presented as a per-
centage of the maximal fluorescence (16,000)
obtained with SMA alone (open diamond).
(B) BiP increases the fraction of soluble SMA.
Aggregation reactions were performed as in
(A). After 96 hr of incubation, samples were
centrifuged for 15 min at 16,000 3 g, and
soluble (S) and pellet (P) fractions were ana-
lyzed by reducing SDS-PAGE (10% acryl-
amide for BiP; 16% acrylamide for SMA) and
visualized by Coomassie blue staining.
(C) Inhibition of fibrillogenesis is specific to
Hsp70 family members. SMA fibril formation
was assayed after 92 hr with 100 mol of SMA
per mol of BiP, Hsp70, GRP94, or lysozyme
(n 5 3). Results were normalized to the maximal fluorescence of SMA alone (14,000 6 1,900).
(D) Cycles of binding and release are not essential for BiP inhibition of fibril formation. Wild-type BiP (100 mol of SMA per mol of BiP) inhibited
SMA fibril formation in the presence of ADP (0.5 mM; open triangles) and was slightly less effective in the presence of ATP (0.5 mM; filled
triangles). The mutant T19G BiP (100 mol of SMA per mol of T19G BiP) inhibited fibril formation irrespective of nucleotide addition (0.5 mM
ADP, open circles; 0.5 mM ATP, filled circles). Thioflavin T fluorescence measurements were compared to the amount of fluorescence generated
by SMA alone (open squares; 10,000 6 6,400; n 5 2).
(E) Prebinding peptide blocks the ability of BiP to inhibit fibrillogenesis. T19G BiP (5.3 mM) was preincubated for 30 min in the presence (open
diamonds) or absence (filled diamonds) of FYQLALT (1 mM) and added to a standard aggregation reaction (160 mM SMA). Lysozyme (5.3 mM)
was similarly incubated in the presence (open squares) or absence (filled squares) of FYQLALT before addition to SMA. Shown is a representative
experiment with triplicate reactions.
(F) BiP is converted to the active, monomeric form when incubated with SMA or FYQLALT. Assay endpoints (96 hr) were centrifuged for 10
min to remove insoluble material, soluble fractions were analyzed on native gels (14% acrylamide), and BiP bands were visualized by Coomassie
blue staining. Under these conditions SMA does not enter the gel. Lanes: 1, BiP alone (8 mg); 2, BiP plus SMA (40 mg); 3, BiP prebound to
FYQLALT (1 mM) added to SMA.
into fibrils even at 16 mM, a concentration ten times A BiP Target Peptide Also Inhibits Fibril Formation
BiP’s ability to inhibit fibril formation suggests that expo-lower than typically used in our assay (Figure 1C), sug-
gests that the inhibition by BiP is not due to lowering sure of a BiP binding site within VL leads to aggregation
of SMA monomers. It follows that an excess of freethe effective concentration of LC below a required
threshold. Rather, the data suggest that BiP inhibits the peptide corresponding to this sequence should also
prevent fibril formation. To test this hypothesis, 18 syn-formation of a nucleation intermediate, presumably the
rate-limiting step in the aggregation reaction (Harper thetic peptides spanning most of the VL sequence, in-
cluding known BiP binding peptides, were examined forand Lansbury, 1997). A likely mode of action is capping
the growth of a large SMA oligomer. their ability to prevent SMA fibril formation when present
at a 5-fold molar excess (Figure 4A). Most peptides wereThe ability of BiP to inhibit SMA fibril assembly was
dependent on its normal peptide binding activity. Wild- inert with respect to fibril formation. However, PKLLIYWA
(amino acids 44–51) exhibited partial inhibition, and thetype BiP inhibited fibrillogenesis in the presence of ADP,
and inclusion of ATP decreased the efficiency of BiP overlapping peptides TDFTLTI (69–75) and FTLTISS (71–
77) showed marked inhibition of fibril formation (Figureactivity only slightly (Figure 3D). Addition of ATP to a
BiP mutant (T19G) did not affect its ability to inhibit fibril 4A). Furthermore, in the presence of the latter two pep-
tides, SMA remained soluble (data not shown). Anotherassembly (Figure 3D). This mutant has the same on rate
for substrate as wild-type BiP but does not release sub- version of this 71–77 peptide, FTLKISR, commonly found
in a number of VL germline genes (Huber et al., 1993),strate in the presence of ATP (Wei et al., 1995). Prebind-
ing of T19G BiP with the peptide FYQLALT (a high- inhibited as well as FTLTISS and also inhibited fibril
assembly of a l6 VL protein (data not shown). Interest-affinity pan-Hsp70 substrate, not derived from LC;
Takeda and McKay, 1996) blocked the chaperone’s abil- ingly, the 69–77 sequence was one of two dominant BiP
binding sites that we had identified previously (Davis etity to suppress fibril assembly (Figure 3E). Furthermore,
BiP progressively converts to its monomeric form upon al., 1999). The other one is inaccessible to BiP under
our reaction conditions because it is buried by the for-incubation with SMA (Figure 3F), as observed for BiP–
peptide interactions (Freiden et al., 1992; Blond-Elguindi mation of the VL disulfide bond.
We determined the specific structural features of theet al., 1993b). Taken together, these experiments show
that while BiP’s ability to interfere with fibril assembly sequence required for activity as an aggregation inhibi-
tor (Figure 4B). A derivative of the FTLKISR (71–77) pep-is dependent on its normal mode of substrate binding,
this activity does not strictly require cycles of binding tide in which Lys-74 was replaced with Glu had an inter-
mediate effect on fibril formation; a peptide in whichand release. Presumably, BiP can both bind to the ag-
gregating VL unit and prevent formation of the critical Phe-71 and Ile-75 were replaced by Leu was also an
effective inhibitor. However, several substitutions abol-nucleation intermediate.
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due to the fact that only a fraction of the input peptide
actually adopts the relevant conformation that makes it
an effective inhibitor when added as a free heptameric
peptide. Alternatively, the affinity of the free peptide for
its binding site may be lower than that of BiP for VL.
BiP Inhibits SMA Aggregation in Cells
To demonstrate that the interaction of SMA with BiP in
vitro is physiologically relevant, complete LEN and SMA
LC were expressed in COS cells. As with any other wild-
type LC, LEN was secreted and exhibited reticular ER
staining (Figure 5A, arrows) as well as perinuclear Golgi
staining. This staining pattern was not the predominant
feature observed with SMA. Instead, there was diffuse
staining throughout the cytoplasm and, remarkably, in-
tranuclear staining (Figure 5B). This pattern was consis-
tent with the nonsecreted phenotype of SMA and its
degradation by proteasomes, demonstrated by pulse–
chase and inhibitor studies presented elsewhere (Dul et
al., submitted). Approximately 30% of cells expressing
SMA have a single, large, perinuclear inclusion body
(Figure 5B, arrowhead) similar to what is observed when
degradation of the cystic fibrosis transmembrane con-
ductance regulator is blocked (Johnston et al., 1998).
Coexpression of wild-type BiP did not significantly
decrease the cytoplasmic pool of SMA (compare the
diffuse kappa distribution in Figure 5B with the distinct
reticular pattern of BiP in the same cells; Figure 5C).
However, coexpression of wild-type BiP did decrease
the number of cells with inclusion bodies (Figure 5F).
Figure 4. VL-Derived Peptides Inhibit Fibril Formation
Coexpression of the mutant T19G BiP caused a pro-
(A) Heptameric peptides derived from the VL sequence as indicated nounced shift in the staining pattern: the ER localizationwere tested for their ability to inhibit SMA fibrillogenesis (80 mM VL,
of SMA was dramatically increased, accompanied by a400 mM peptide per assay, monitored for 100 hr). The effectiveness
reciprocal decrease in diffuse cytoplasmic and nuclearof each peptide is indicated by the degree of shading, from inhibitory
(peptides 69–75 and 71–77, black bars) to ineffective (e.g., 1–7, open staining (note the coincident reticular staining with anti-
bars). kappa and anti-BiP; Figures 5D and 5E). Expression of
(B) Alternating hydrophobic residues and extended conformation this nonreleasing BiP variant reduced the number of
are required for peptide inhibition of fibrillogenesis. Derivatives of
cells with inclusion bodies to a similar extent as expres-the FTLTISS peptide were tested for their inhibitory capacity as in
sion of wild-type BiP (Figure 5F). Thus, overexpression(A), at a 5:1 peptide to SMA ratio.
of either wild-type or nonreleasing BiP resulted in re-(C) Dose-dependent inhibition by FTLTISS. Increasing concentra-
tions of the inhibitory peptide FTLTISS or the noninhibitory peptide duced SMA aggregation in vivo.
TRIFSKL were added to a standard aggregation reaction as in (A) The difference between intracellular SMA and LEN
and fibril formation was measured over time at each peptide concen- was also evident biochemically; in a detergent solubility
tration. The extent of SMA fibril formation at 45 hr in the presence
assay, the level of soluble SMA was low compared toof various concentrations of peptides is plotted relative to that of
LEN (Dul et al., submitted). Importantly, coexpressionSMA alone at 45 hr. This time point was chosen because it was
of BiP increased the level of soluble SMA 3-fold (Figurethe time required for half-maximal fibril formation with no inhibitor
present. 6), consistent with the effects seen by immunofluores-
cence. Thus, the relevance of the antiamyloid activity
of BiP in vitro is supported by its ability to suppress
intracellular aggregation of LC.ished the inhibitory capacity of the resulting peptides.
Peptides with proline at position 74 or alanine in place
of the hydrophobic residues at position 71, 73, or 75 Discussion
each failed to inhibit aggregation. Lastly, a peptide with
a scrambled version of the FTLKISR sequence also did We have reconstituted fibril formation in vitro by an
amyloid-derived LC and studied its aggregation in anot affect aggregation. Thus, the same features of the
peptide that are required for its ability to bind BiP, alter- cellular model. The results relate the tendency to aggre-
gate to the somatic hypermutation process and suggestnating hydrophobic residues and an extended confor-
mation (Blond-Elguindi et al., 1993a), are also necessary a molecular mechanism for LC amyloidogenesis. The
data also demonstrate that a key feature of normal LCfor inhibition of fibrillogenesis.
The ability of FTLTISS to inhibit fibrillogenesis was folding, interaction with the molecular chaperone BiP,
is a major determinant of the fate of this LC. This sug-concentration dependent, but in contrast to BiP or
Hsp70, stoichiometric levels of peptide were required gests a possible mode of therapeutic intervention.
In vitro, SMA readily polymerized into fibrils resem-for this inhibition (Figure 4C). The difference is likely
Immunity
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Figure 5. Coexpression of BiP with SMA Decreases Its Intracellular Aggregation
Localization of complete LC of LEN (A), SMA ([B] and [D]), wild-type HA-BiP (C), and HA-T19G BiP (E) in transfected COS cells. Following
transfection, cells were processed for immunofluorescence with antibody to human kappa LC or HA.
(A–C) LEN exhibits the ER (arrows) and Golgi staining typical of a wild-type protein (A). SMA shows primarily cytoplasmic staining, which
obscures its ER localization (B). SMA is also frequently found in perinuclear inclusions ([B], inset, arrowhead). Coexpressed wild-type HA-BiP
exhibits its normal ER distribution (arrows) in the same cells and does not inhibit cytoplasmic localization of SMA (compare [C] with [B]).
(D and E) Coexpression of SMA with nonreleasing BiP retains SMA in the ER. In cells coexpressing SMA and HA-T19G BiP, SMA exhibits a
more prominent ER distribution (arrows) and decreased cytoplasmic staining.
(F) Quantitation of the effect of BiP on SMA localization. Cells cotransfected with SMA and either wild-type HA-BiP or HA-T19G BiP were
scored for ER (as in [D]) or cytoplasmic (as in [B]) localization of SMA and for the presence of inclusion bodies (as in [B], inset). Stippled bars,
cytoplasmic staining; filled bars, ER staining; open bars, presence of inclusion bodies (n 5 80 cells for each condition).
bling the amyloid fibrils detected in patients, while LEN different LC coexist in the circulation. Highly homolo-
gous LC can be found in physical proximity and at suffi-remained soluble unless partially denatured with GuHCl.
Aggregation of SMA was nucleation dependent and its ciently high concentrations to cross-associate at several
sites in the body, such as the kidneys and the lymphrate was enhanced by incubation with preformed SMA
fibrils. Remarkably, even in the absence of denaturants nodes. The germinal center in particular provides an
opportunity for cross-seeding, since it is initiated byor somatic mutation, LEN was induced to form fibrils by
seeding with SMA fibrils. Our data also show that the oligoclonal populations of B cells residing in one location
and undergoing somatic hypermutation (Kepler and Per-distinct aggregation behavior of the two proteins is gov-
erned by as little as one amino acid change, substitution elson, 1993). If SMA or a similar aggregation-prone LC
is secreted and aggregates in the extracellular space,of the highly conserved Pro-40 with Leu. Hence, despite
the thermodynamic stability of the germline k4 se- LEN or other related LC secreted from neighboring cells
may be induced to aggregate. A second possible mech-quence, it can be easily converted to a fibrillogenic vari-
ant. This phenomenon is similar to that observed with anism for cross-aggregation occurs if an LC aggregates
within a B cell or a plasma cell (see below), with subse-prion proteins, where molecules in a native conformation
can be converted to an alternative, aggregation-prone quent apoptotic death. Aggregated material released in
this fashion can come in contact with secreted LC fromconformation merely by association with the aggregat-
ing conformer (Kocisko et al., 1994; Tuite and Lindquist, neighboring cells. If the local concentration of a given
LC is high enough, and we show here that the critical1996). Such inherent susceptibility to induced conforma-
tional changes may explain why 10 of 12 known k4 concentration is close to physiological levels, growth of
fibrils could occur via conversion of the wild-type LCfamily LC form either amyloid fibrils or amorphous de-
posits (Stevens et al., 1999). into the fibril forming conformation.
Statistical estimates and sequence data both indicateThe ability of an LC fibril to induce fibrillogenesis of
a normal LC might be a common and unappreciated that mutations promoting aggregation occur at a sur-
prisingly high frequency (Stevens and Argon, 1999a). Aspathological event. Since LC are produced and secreted
in excess of heavy chains (Shapiro et al., 1966), many we show here, wild-type LEN is only one or two somatic
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1998; Davis et al., 1999), the LC domain whose folding
is potentially destabilized by somatic mutations. Thus,
BiP is a built-in sensor of the folding quality of this
domain.
BiP is also part of the machinery that translocates
proteins into and out of the ER in every cell (Brodsky et
al., 1995, 1999; Hamman et al., 1998). In the case of
SMA, persistent association with a nonreleasing BiP
variant traps enough SMA in the ER to be detectable
by microscopy, with less SMA dislocated to the cytosol
for either proteasomal degradation or aggregation into
inclusion bodies (Figure 5 and Dul et al., submitted).
Wild-type BiP, which can undergo repeated cycles of
substrate binding and release, appears to retain SMA
in the ER less effectively, although its expression does
decrease the appearance of inclusion bodies. Suppres-
sion of aggregation in vivo by both wild-type and mutant
BiP parallels their respective activities in vitro. Finally,
BiP is present in the ER of plasma cells at vast molar
excess over LC (Wiest et al., 1990), providing sufficient
quality control capacity even after differentiation of B
cells into a state of high antibody production. Such ac-
Figure 6. Solubility of Intracellular SMA with and without Coex- tion by BiP may also explain why intra-ER LC amyloids
pressed BiP are rare (Ishihara et al., 1991). Further biochemical stud-
SMA-expressing cell lysates were separated into soluble (S) and ies to define the chaperone requirements of dislocation
insoluble fractions (P) and analyzed by immunoblotting. to the cytosol and of inclusion body formation are cur-
(A) Levels of SMA coexpressed with an irrelevant protein (–) or
rently in progress.coexpressed with wild-type HA-BiP (1BiP).
Our data show that the substitution of Pro-40 with(B) Quantitation of SMA levels from four experiments as in (A), where
Leu largely accounts for the aggregation behavior ofthe level of SMA expression in (–) samples is set at 1.
SMA. The importance of Pro-40 for amyloidosis (this
study and Stevens et al., 1999) suggests a molecular
mutations away from becoming aggregation prone. Yet model for fibril formation by VL. Position 40 in all k germ-
pathologic LC are rare in the expressed repertoire. This line genes is occupied by Pro, and hydrophobic substi-
implies that the immune system employs quality control tutions at this position are highly correlated with amyloid
mechanisms to sense the effects of mutations and pre- formation (Stevens et al., 1999). Inspection of the LEN
vent expression of unstable LC. Our data suggest that crystal structure (Huang et al., 1994) shows that Pro-40
BiP is a key quality control component in lymphoid cells forms a b turn, allowing b strands C and C9 to interact
through its ability to identify misfolded proteins like SMA (Figure 7A). Leu at position 40 likely compromises the
and direct them to degradation. We previously showed positioning of strand C and may displace the Gln-38
that BiP’s association with newly synthesized LC is an side chain known to be critically involved in V domain
obligatory step in the folding pathway (Hendershot et interactions (Pokkuluri et al., 1998). Furthermore, the
P40L substitution may displace Lys-39, disrupting theal., 1996). BiP binds primarily to VL (Skowronek et al.,
Figure 7. Model of VL Fibril Formation
(A) Ribbon diagram of a LEN monomer, illustrating the positions of Pro-40 and Lys-39 with respect to the salt bridge formed by Arg-61 and
Asp-82. The loop from residue 61 to residue 82 that contains the peptide 69–77 is highlighted as a thicker ribbon. Strand C, containing Gln-
38 (located to the left of the indicated Lys-39), and strand C9 are denoted with arrows.
(B) Ribbon diagram of LEN, illustrating the proposed conformational change in the mobile loop (thick ribbon), as compared to the native state
(A). The three alternate hydrophobic amino acids whose side chains are highlighted provide a docking site for BiP, and the space they vacate
provides a docking site for the inhibitory peptides shown in Figure 4. Only a monomer is shown for simplicity, though the aggregating unit is
postulated to be a dimer.
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Purification of BiP, Hsp70, and GRP94hydrogen bond network among Lys39-Glu81-Arg61-
His6-tagged murine BiP was produced and purified as in Davis etAsp82 (Figure 7A). This network is essential for a stable
al. (1999), with one modification: the ATP column was replaced withVL fold and holds a potentially mobile VL loop (amino a Mono Q column. The purity of the BiP preparations was .95%,
acids 61–82) in place (Wetzel, 1997; Stevens and Argon, as judged by gel electrophoresis. The GeneEditor site-directed mu-
1999a). tagenesis system (Promega, Madison, WI) was used to generate
the T19G substitution in wild-type His6-tagged murine BiP, creatingPreviously, we showed that the nonamer TDFTLTISS
a nonreleasing BiP mutant, as described in Wei et al. (1995). A(residues 69–77) is one of two LC peptides with high
bacterial expression plasmid with the inducible form of the humanaffinity for BiP (Davis et al., 1999). Here we show that
hsp70 gene was obtained from Dr. R. Morimoto (Northwestern Uni-this peptide is an effective inhibitor of fibrillogenesis.
versity, Evanston, IL). Recombinant Hsp70 was purified on succes-
This peptide does not inhibit other types of LC aggrega- sive Mono Q ion exchange and ATP columns as described (Freeman
tion (data not shown), highlighting the specificity of the et al., 1995). Recombinant canine GRP94 was produced in SF9 cells
from a baculovirus expression vector and purified on successiveconformational change leading to fibril assembly. More-
Mono Q and Con A columns.over, the same features required for inhibiting aggrega-
tion are necessary for this peptide’s binding to BiP (Ge-
Fibrillogenesis Assaything et al., 1995). Thus, the ability of both BiP and its
Amyloid VL fibrils were formed by agitating (250 rpm, 378C) 160 mMtarget VL peptide to inhibit aggregation suggests that, VL in PBS, in the presence or absence of GuHCl buffered to pH 7.5
under aggregation-promoting conditions, the loop con- (Solomon et al., 1998; Raffen et al., 1999). Aliquots were added to
taining the TDFTLTISS peptide is not anchored properly a solution of 10 mM thioflavin T and fluorescence measured (excita-
tion, 440 nm; emission, 490 nm). Reactions were routinely monitoredin the body of the VL (Figure 7). These considerations
for changes in turbidity at 405 nm. Gel electrophoresis was alsolead us to propose that destabilization of the mobile
used to measure the fraction of input protein that aggregated. SMAloop, amino acids 61–82, allows it to participate in a
was resolved on 16% and BiP on 10% SDS gels. Native gels for BiP
swapped domain interaction (Bennett et al., 1995) with were made using the same solutions without detergent or reducing
other VL. BiP may inhibit fibril formation by binding to agents.
molecules whose TDFTLTISS peptide is exposed,
thereby inhibiting the ability to add aggregating units to Seeding Amyloid Fibrillogenesis
Preformed fibrils, obtained from endpoints of the SMA fibril assay,the polymer, as well as “capping” a nucleation interme-
were prepared either by sonication with a probe for 30 s at 48C ordiate. Thus, substoichiometric levels of BiP can inhibit
by extensive vortexing. These processed fibrils were added at thefibril formation even without the ability to cycle between
beginning of the fibrillogenesis assay at 5% w/w of the soluble VLsubstrate binding and release. The free 69–77 peptide unless otherwise noted. At time zero the amount of thioflavin T
may inhibit fibril formation as a competitive inhibitor, fluorescence was measured. This value was subtracted from read-
occupying a crevice vacated by that loop during partial ings taken at later time points to eliminate the fluorescence contrib-
uted by the seed.domain unfolding (Figure 7). The ability of BiP to reduce
SMA aggregation in COS cells (this paper) and additional
Inhibitory Peptidesdata showing that the TDFTLTISS peptide reduces ag-
Peptides were synthesized either at the University of Chicago facilitygregation in cells (Dul et al., submitted) provide physio-
or by New England Peptide Inc. Stock solutions were prepared with
logical relevance to this molecular model. dimethylsulfoxide.
Variable domains are but one example of proteins with
a b domain fold that are amyloidogenic. b2-microglobu- Electron Microscopy
VL fibrils were adhered to glow-discharged, formvar carbon-coatedlin, transthyretin, and superoxide dismutase are exam-
grids, negatively stained with 1% uranyl acetate, washed with deion-ples of other proteins known to participate in protein
ized water, and viewed with a JEOL 100-CX2 microscope operatedaggregation diseases (Deng et al., 1993; Brancaccio et
at 80 kV.
al., 1995; Kelly et al., 1997). Domains with a Greek key
fold may be intrinsically vulnerable to diffusion of anti- Transfection and Fluorescence Microscopy
parallel b hairpin loops that expose conformationally Plasmids directing expression of complete SMA and LEN LC
critical sites (Kelly et al., 1997). Thus, improved under- were derived by subcloning the respective VL sequences from
pkIVsma007 and pkIVlen004 into the vector pJDE (Dul and Argon,standing of the interactions between chaperones and b
1990) that contained a mouse kappa signal sequence and the humandomain proteins may reveal critical features that under-
kappa constant region. The wild-type trypanosome BiP gene,lie a broad range of fibril formation phenomena. Identifi-
tagged at the C terminus with the influenza hemagglutinin peptide
cation of these specific structural features should facili- (HA-BiP), was a gift of Dr. Jay Bangs (University of Wisconsin, Madi-
tate future development of rational strategies for drug son, WI). It was subcloned into the mammalian expression vector
discovery across the spectrum of amyloid diseases (Kis- pBCMGSneo (Karasuyama et al., 1993). The T19G mutation was
introduced into the latter construct (HA-T19G BiP) with the GeneEdi-ilevsky et al., 1995; Merlini et al., 1995; Tjernberg et al.,
tor system (Promega). COS-1 cells were grown on coverslips and1996; Soto et al., 1998; Oza et al., 1999).
transiently transfected with FuGENE 6 transfection reagent (Roche)
according to manufacturer’s instructions. In cotransfection experi-Experimental Procedures
ments, equal amounts (w/w) of DNA for SMA and HA-BiP or HA-
T19G BiP were used. Two days later the cells were fixed, permeabil-Purification of SMA, LEN, and SMA-Derived LEN
ized, and stained as previously described (Burkhardt et al., 1993)Mutant Variable Domains
using the following antibodies: FITC-conjugated goat anti-humanSMA and LEN VL domains were expressed in the Escherichia coli
kappa (BioSource), mouse monoclonal anti-HA (BAbCO), and don-strain JM83 from the plasmids pkIVsma007 and pkIVlen004 (Stevens
key anti-mouse IgG conjugated to Texas Red (Jackson Labs).et al., 1995), respectively. Mutant LEN VL domains containing single
amino acid substitutions found in the SMA sequence were described
Solubility Assaypreviously (Raffen et al., 1998). Recombinant proteins were purified
COS cells transfected with SMA were scraped and lysed on ice infrom the periplasmic fraction as in Wilkins Stevens et al. (1995).
Their purity was 95% or better, as judged by gel electrophoresis. 50 mM Tris (pH 8.0)/150 mM NaCl/5 mM KCl/5 mM MgCl2/0.5%
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Triton X-100/0.5% deoxycholate/20 mM NEM, supplemented with W.Y., Getzoff, E.D., Hu, P., Herzfeldt, B., Roos, R.P., et al. (1993).
Amyotrophic lateral sclerosis and structural defects in Cu,Zn super-a cocktail of protease inhibitors. Lysates were centrifuged at
16,000 3 g for 15 min and separated into soluble and insoluble oxide dismutase. Science 261, 1047–1051.
fractions. Pellets were resolubilized in 60 mM Tris (pH 6.8)/5% SDS/ Denoroy, L., Deret, S., and Aucouturier, P. (1994). Overrepresenta-
10% glycerol with 1 min sonication, followed by boiling. Equal total tion of the V kappa IV subgroup in light chain deposition disease.
protein was loaded on reducing SDS gels and SMA detected by Immunol. Lett. 42, 63–66.
immunoblotting. Primary antibody was goat anti-human kappa (Bio-
Dul, J.L., and Argon, Y. (1990). A single amino acid substitution in the
Source); secondary antibody was HRP-conjugated donkey anti-goat
variable region of the light chain specifically blocks immunoglobulin
Ig (Santa Cruz Biotechnology). Blots were developed with SuperSig-
secretion. Proc. Natl. Acad. Sci. USA 87, 8135–8139.
nal Substrate (Pierce) and quantified using scanning and NIH Image
Freeman, B.C., Myers, M.P., Schumacher, R., and Morimoto, R.I.1.6 software.
(1995). Identification of a regulatory motif in Hsp70 that affects AT-
Pase activity, substrate binding and interaction with HDJ-1. EMBOAcknowledgments
J. 14, 2281–2292.
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